Colorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor γ (PPARG, PPARgamma) Is Associated With Good Prognosis

Gastroenterology

Volumn 136, Issue 4, 2009, Pages 1242-1250

  Ogino, Shuji ^a,b,c   Shima, Kaori ^a   Baba, Yoshifumi ^a   Nosho, Katsuhiko ^a   Irahara, Natsumi ^a   Kure, Shoko ^a   Chen, Li ^b   Toyoda, Saori ^a   Kirkner, Gregory J ^b   Wang, Y Lynn ^d   Giovannucci, Edward L ^b,c   Fuchs, Charles S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; CYCLOOXYGENASE 2; FATTY ACID SYNTHASE; P21 ACTIVATED KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CPG ISLAND; DNA EXTRACTION; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR LOCALIZATION;

EID: 62949100452     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.12.048     Document Type: Article

References (53)

1. Tontonoz P., and Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77 (2008) 289-312
2. Wang Y.L., and Miao Q. To live or to die: prosurvival activity of PPARgamma in cancers. PPAR Res 2008 (2008) 209629 doi: 10.1155/2008/209629.
3. Sarraf P., Mueller E., Jones D., et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4 (1998) 1046-1052
4. Girnun G.D., Smith W.M., Drori S., et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A 99 (2002) 13771-13776
5. Elrod H.A., and Sun S.Y. PPARgamma and apoptosis in cancer. PPAR Res 2008 (2008) 704165 doi: 10.1155/2008/704165.
6. Yang W.L., and Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22 (2001) 1379-1383
7. Subbaramaiah K., Lin D.T., Hart J.C., et al. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 276 (2001) 12440-12448
8. Burton J.D., Goldenberg D.M., and Blumenthal R.D. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008 (2008) 494161 doi: 10.1155/2008/494161.
9. Thompson E.A. PPARgamma physiology and pathology in gastrointestinal epithelial cells. Mol Cells 24 (2007) 167-176
10. Lefebvre A.M., Chen I., Desreumaux P., et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4 (1998) 1053-1057
11. Saez E., Tontonoz P., Nelson M.C., et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4 (1998) 1058-1061
12. Yang K., Fan K.H., Lamprecht S.A., et al. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice. Int J Cancer 116 (2005) 495-499
13. Osawa E., Nakajima A., Wada K., et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124 (2003) 361-367
14. Cesario R.M., Stone J., Yen W.C., et al. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett 240 (2006) 225-233
15. Theocharis S., Giaginis C., Parasi A., et al. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. Dig Dis Sci 52 (2007) 2305-2311
16. Gustafsson A., Hansson E., Kressner U., et al. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 121 (2007) 232-240
17. Konstantinopoulos P.A., Vandoros G.P., Sotiropoulou-Bonikou G., et al. NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma "on/off" switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int J Colorectal Dis 22 (2007) 57-68
18. Van Rijnsoever M., Elsaleh H., Joseph D., et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 9 (2003) 2898-2903
19. Ward R.L., Cheong K., Ku S.L., et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 21 (2003) 3729-3736
20. Samowitz W.S., Sweeney C., Herrick J., et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65 (2005) 6063-6069
21. Popat S., Hubner R., and Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23 (2005) 609-618
22. Barault L., Charon-Barra C., Jooste V., et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 68 (2008) 8541-8546
23. Ogino S., Nosho K., Kirkner G.J., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58 (2008) 90-96
24. Ogino S., Nosho K., Kirkner G.J., et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 100 (2008) 1734-1738
25. Ogino S., Nosho K., Kirkner G.J., et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) ; [Epub ahead of print].
26. Colditz G.A., and Hankinson S.E. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 5 (2005) 388-396
27. Chan A.T., Ogino S., and Fuchs C.S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356 (2007) 2131-2142
28. Rimm E.B., Stampfer M.J., Colditz G.A., et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1 (1990) 466-473
29. Ogino S., Kawasaki T., Brahmandam M., et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7 (2005) 413-421
30. Nosho K., Kawasaki T., Ohnishi M., et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10 (2008) 534-541
31. Ogino S., Kawasaki T., Kirkner G.J., et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9 (2007) 305-314
32. Eads C.A., Danenberg K.D., Kawakami K., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28 (2000) E32
33. Ogino S., Kawasaki T., Brahmandam M., et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8 (2006) 209-217
34. Ogino S., Cantor M., Kawasaki T., et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55 (2006) 1000-1006
35. Weisenberger D.J., Siegmund K.D., Campan M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38 (2006) 787-793
36. Ogino S., Kawasaki T., Nosho K., et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 122 (2008) 2767-2773
37. Yang A.S., Estecio M.R., Doshi K., et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 32 (2004) e38
38. Nosho K., Kawasaki T., Chan A.T., et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 53 (2008) 588-598
39. Kawasaki T., Nosho K., Ohnishi M., et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 9 (2007) 569-577
40. Ogino S., Kawasaki T., Kirkner G.J., et al. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 20 (2007) 15-22
41. Ogino S., Meyerhardt J.A., Cantor M., et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 11 (2005) 6650-6656
42. Ogino S., Brahmandam M., Cantor M., et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19 (2006) 59-68
43. Grady W.M., and Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135 (2008) 1079-1099
44. Goel A., Nagasaka T., Arnold C.N., et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132 (2007) 127-138
45. Ponferrada A., Caso J.R., Alou L., et al. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 132 (2007) 1791-1803
46. Chung S.K., Lee M.G., Ryu B.K., et al. Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses. Gastroenterology 132 (2007) 2459-2477
47. Konishi K., Shen L., Wang S., et al. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology 132 (2007) 1254-1260
48. Shin S.K., Nagasaka T., Jung B.H., et al. Epigenetic and genetic alterations in netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology 133 (2007) 1849-1857
49. Kawamura Y.I., Toyota M., Kawashima R., et al. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 135 (2008) 142-151e3.
50. Govindarajan R., Ratnasinghe L., Simmons D.L., et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25 (2007) 1476-1481
51. Chen Y.Q., Edwards I.J., Kridel S.J., et al. Dietary fat-gene interactions in cancer. Cancer Metastasis Rev 26 (2007) 535-551
52. Menendez J.A., and Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7 (2007) 763-777
53. Meyerhardt J.A., Giovannucci E.L., Holmes M.D., et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 24 (2006) 3527-3534